The features of prevalent activating mutations in BRAF and the high mutational burden in melanoma have been explored for targeted therapy with the combination of BRAF and MEK inhibitors [9] and immunotherapy involving immune checkpoint blockade (ICB), anti-CTLA-4 (cytotoxic T-lymphocyte antigen-4) antibody (ipilimumab) and anti-PD-1 (programmed cell death 1) antibodies (nivolumab and pembrolizumab) [10]. Here, CTLA4 is linked to melanoma.